STERIS plc $STE Stock: Foster Victor Wealth Advisors LLC Grows Stake

Foster Victor Wealth Advisors LLC grew its holdings in shares of STERIS plc (NYSE:STE) by 2.8% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 92,031 shares of the medical equipment provider’s stock after purchasing an additional 2,503 shares during the quarter. STERIS makes up approximately 0.9% of Foster Victor Wealth Advisors LLC’s holdings, making the stock its 28th biggest position. Foster Victor Wealth Advisors LLC owned about 0.09% of STERIS worth $20,428,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Axxcess Wealth Management LLC purchased a new position in shares of STERIS in the third quarter worth approximately $227,000. Crossmark Global Holdings Inc. grew its position in STERIS by 4.4% during the third quarter. Crossmark Global Holdings Inc. now owns 6,726 shares of the medical equipment provider’s stock valued at $1,412,000 after buying an additional 281 shares during the period. Strengthening Families & Communities LLC grew its position in STERIS by 0.6% during the third quarter. Strengthening Families & Communities LLC now owns 10,884 shares of the medical equipment provider’s stock valued at $2,286,000 after buying an additional 61 shares during the period. Carnegie Investment Counsel increased its holdings in STERIS by 1.8% during the third quarter. Carnegie Investment Counsel now owns 62,597 shares of the medical equipment provider’s stock valued at $13,146,000 after buying an additional 1,121 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in STERIS by 20.3% during the third quarter. Nisa Investment Advisors LLC now owns 16,158 shares of the medical equipment provider’s stock valued at $3,393,000 after buying an additional 2,729 shares during the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock.

STERIS Stock Down 1.8%

STE stock opened at $221.12 on Thursday. STERIS plc has a twelve month low of $195.14 and a twelve month high of $269.44. The company has a quick ratio of 1.35, a current ratio of 1.91 and a debt-to-equity ratio of 0.23. The stock has a market cap of $21.56 billion, a P/E ratio of 27.03 and a beta of 0.92. The business’s 50-day moving average price is $220.17 and its 200-day moving average price is $217.96.

STERIS (NYSE:STE) last announced its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.49 by $0.10. STERIS had a return on equity of 14.34% and a net margin of 13.34%. The company had revenue of $1.49 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the previous year, the company posted $2.34 EPS. The firm’s revenue was up 7.3% on a year-over-year basis. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. On average, equities research analysts forecast that STERIS plc will post 11.12 EPS for the current year.

STERIS Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 25th. Shareholders of record on Friday, September 4th were given a $0.69 dividend. The ex-dividend date was Friday, September 4th. This is an increase from STERIS’s previous quarterly dividend of $0.63. This represents a $2.76 dividend on an annualized basis and a dividend yield of 1.2%. STERIS’s dividend payout ratio (DPR) is currently 33.74%.

Insider Buying and Selling at STERIS

In other news, Director Mohsen Sohi sold 4,058 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $235.78, for a total value of $956,795.24. Following the completion of the sale, the director directly owned 24,305 shares of the company’s stock, valued at $5,730,632.90. This represents a 14.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.12% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms have weighed in on STE. UBS Group decreased their price target on shares of STERIS from $275.00 to $270.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Weiss Ratings reissued a “hold (c)” rating on shares of STERIS in a research report on Monday, August 24th. Piper Sandler restated an “overweight” rating and issued a $275.00 price objective (up from $270.00) on shares of STERIS in a research note on Friday, August 7th. Finally, Wall Street Zen lowered STERIS from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 11th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, STERIS presently has an average rating of “Moderate Buy” and an average target price of $271.33.

About STERIS

STERIS plc (NYSE: STE) provides products and services designed to support infection prevention, procedural care and the safe manufacture of healthcare and life sciences products. Its offerings include surgical equipment and operating-room solutions, sterilization and decontamination systems, endoscopy products, cleaning and disinfection technologies, and related consumable products.

The company also provides outsourced sterilization and laboratory services through its Applied Sterilization Technologies business.